Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782872 · ClinicalTrials.gov registry record · Phase 4
Analgesia After Total Shoulder Arthroplasty
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT01782872 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 80 participants.
The verdict
NCT01782872, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which medication(s) should be included in the interscalene nerve block (an injection of local anesthetic \[numbing medicine\] near nerves in the shoulder) for patients undergoing total shoulder arthroplasty (shoulder replacement). The ideal nerve block would reduce pain after shoulder surgery without causing a great deal of muscle weakness.
Interventions
- PROCEDURE Interscalene Block (ISB) - 0.375% Ropivacaine + additives
- PROCEDURE Interscalene Block (ISB) - 0.2% Ropivacaine + additives
- PROCEDURE Interscalene Block (ISB) - 0.1% Ropivacaine + additives
- PROCEDURE Interscalene Block (ISB) - Systemic Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01782872
The ClinicalTrials.gov registry entry for NCT01782872 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Interscalene Block (ISB) - 0.375% Ropivacaine + additives is the first listed.
NCT01782872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01782872 about?
NCT01782872 is a clinical study titled "Analgesia After Total Shoulder Arthroplasty". The purpose of this study is to determine which medication(s) should be included in the interscalene nerve block (an injection of local anesthetic \[numbing medicine\] near nerves in the shoulder) for patients undergoing total shoulder arthroplasty (shoulder replacement). The ideal nerve block would...
What is the current status of trial NCT01782872?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2012-10. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01782872?
The interventions under investigation include: Interscalene Block (ISB) - 0.375% Ropivacaine + additives (PROCEDURE), Interscalene Block (ISB) - 0.2% Ropivacaine + additives (PROCEDURE), Interscalene Block (ISB) - 0.1% Ropivacaine + additives (PROCEDURE), Interscalene Block (ISB) - Systemic Control (PROCEDURE).
Who is sponsoring clinical trial NCT01782872?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.